Harold Keer

Corporate Officer/Principal en Stanford University .

Health Technology

Consumer Services

Cargos activos de Harold Keer

Empresas	Cargo	Inicio	Fin
Stanford University	Corporate Officer/Principal	-	-

Empresas	Cargo	Inicio	Fin
EXELIXIS, INC.	Director Técnico/Científico/I+D	06/07/2011	-
EXELIXIS, INC.	Corporate Officer/Principal	-	06/07/2011
TITAN PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-
FIVE PRIME THERAPEUTICS, INC.	Director Técnico/Científico/I+D	06/07/2011	-
FIVE PRIME THERAPEUTICS, INC.	Corporate Officer/Principal	-	06/07/2011

Northwestern University

Doctorate Degree

Internacional

Estados Unidos

Operativa

Corporate Officer/Principal	4
Chief Tech/Sci/R&D Officer	2
Doctorate Degree	1

Sectorial

Health Technology	4
Consumer Services	3

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	2
EXELIXIS, INC.	Health Technology
TITAN PHARMACEUTICALS, INC.	Health Technology

Empresas privadas	1
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.	Health Technology

Empresas privadas

Health Technology